Sentinel Node in Cutaneous Malignant Melanoma in the Trunk and Extremities: Experience at the National Cancer Institute, Bogotá, Colombia, 2000-2007
Abstract
Objective: To determine the regional recurrence rate in patients diagnosed with cutaneous malignant melanoma in the trunk and extremities, and with negative sentinel node biopsy.
Methods: A case series was utilized to review patients with clinical registries IB, IIA, IIB, IIIC treated with sentinel node biopsy between January, 2000 and December, 2007. Descriptive analysis was performed and survival analysis carried out with the Kaplan-Meier method.
Results: The study included 170 patients. Median follow-up was 21.5 months, with regional recurrence rate at 11.76%. Overall survival rate at 24 months for negative sentinel node was 100%.
Conclusions: The regional recurrence rate in the series analyzed of patients with melanoma and negative sentinel lymph node is situated within that reported in the literature; however, follow up is relatively short.
Author Biographies
Óscar García, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Édgar Vergara, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Carlos Duarte, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Licet Villamizar, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Sandra Díaz, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Fernando Perry, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
Javier Ángel, Instituto Nacional de Cancerología
Grupo de Cirugía de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
References
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.
https://doi.org/10.3322/canjclin.57.1.43
República de Colombia. Instituto Nacional de Cancerología (INC). Registro institucional de cáncer: anuario estadístico 2006. Bogotá, INC; 2007.
República de Colombia. Instituto Nacional de Cancerología (INC). Registro institucional de cáncer: anuario estadístico 2007. Bogotá: INC; 2008.
República de Colombia. Instituto Nacional de Cancerología (INC). Registro institucional de cáncer: anuario estadístico 2008. Bogotá: INC; 2009.
Balch C, Soong S, Gershenwald JE, et al. Prognostic factor analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-34.
https://doi.org/10.1200/JCO.2001.19.16.3622
Milton GW, Shaw HH, Mc Carthy WJ, et al. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg. 1982;69:108-11.
https://doi.org/10.1002/bjs.1800690217
Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer. 1978;41:948-56.
https://doi.org/10.1002/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z
Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection of stage I melanoma of the limbs. N Eng J Med. 1977;297:627-30.
https://doi.org/10.1056/NEJM197709222971202
Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-30.
https://doi.org/10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2
Morton DL, Wanek L, Nizze J, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491-501.
https://doi.org/10.1097/00000658-199110000-00013
Sim FH, Taylor WF, Pritchard DJ, et al. Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
https://doi.org/10.1016/S0025-6196(12)62768-2
Cascinelli N, Morabito A, Santinami M, et al. Inmediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial, WHO Melanoma Programme. Lancet. 1998;351:793-6.
https://doi.org/10.1016/S0140-6736(97)08260-3
Balch DM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanoma (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87-97.
https://doi.org/10.1007/s10434-000-0087-9
Morton DL, Thompson JF, Cochran AJ, et al. Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
https://doi.org/10.1056/NEJMoa060992
Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151:308-19.
https://doi.org/10.1111/j.1365-2133.2004.06133.x
Morton DL. Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol. 1997;66:267-9.
https://doi.org/10.1002/(SICI)1096-9098(199712)66:4<267::AID-JSO9>3.0.CO;2-9
Piris A, Mihm MC. Progress in melanoma histopathology and diagnosis. Hematol Oncol Clin N Am. 2009;23:467-80.
https://doi.org/10.1016/j.hoc.2009.03.012
Balch CM, Soong S, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-49.
https://doi.org/10.3322/canjclin.54.3.131
McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004; 86:212-23.
https://doi.org/10.1002/jso.20084
República de Colombia.Instituto Nacional de Cancerología (INC). Melanoma: guía de práctica clínica en enfermedades neoplásicas. Bogotá: INC; 2001.
Seaman W, Powers WE. Studies on the distribution of radioactive colloidal gold in regional lymph nodes containing cancer. Cancer. 1995;8:1044-6.
https://doi.org/10.1002/1097-0142(1955)8:5<1044::AID-CNCR2820080530>3.0.CO;2-6
Gould EA, Winship T, Philbin PH, et al. Observations on a sentinel node in cancer of the parotid. Cancer. 1960;13:77-8.
https://doi.org/10.1002/1097-0142(196001/02)13:1<77::AID-CNCR2820130114>3.0.CO;2-D
Cabañas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456-66.
https://doi.org/10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO;2-I
Thompson JF, Niewind P, Uren RF, et al. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res. 1997;7:500-6.
https://doi.org/10.1097/00008390-199712000-00009
Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer stanging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003;10:569-74.
https://doi.org/10.1245/ASO.2003.09.016
Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumorpositive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-84.
https://doi.org/10.1200/JCO.2004.01.012
Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcomes based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17:747-55.
https://doi.org/10.1038/modpathol.3800117
Morton D, Cochran A, Thompson J, et al. Sentinel Node Biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an International Multicenter Trial. Ann Surg. 2005;242:302-13.
https://doi.org/10.1097/01.sla.0000181092.50141.fa
Hettiaratchy SP, Kange N, O'Tootle G, et al. Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients. Br J Plast Surg. 2000;53:559-662.
https://doi.org/10.1054/bjps.2000.3409
Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141:728-35.
https://doi.org/10.1016/j.surg.2006.12.018
Morton D, Cochran A, Thompson J, Elashoff R, Essner R, Glass EC, et al. Sentinel Node Biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an International Multicenter Trial. Ann Surg 2005; 242: 302-313.
https://doi.org/10.1097/01.sla.0000181092.50141.fa
Rughani MG, Swan MC, Adams TS, Middleton MR, Ramcharan RN, Pay A, et al. Sentinel lymph node biopsy in melanoma: the Oxford ten year clinical experience. J Plast Reconstr Aesthet Surg 2011: 64 (10): 1284-1290.
https://doi.org/10.1016/j.bjps.2011.05.001
Satzger I, Meier A, Hoy L, Völker B, Kapp A, Hauschild A, et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up: Ann Surg Oncol 2011; 18: 514-520.
https://doi.org/10.1245/s10434-010-1318-3
Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87-97.
https://doi.org/10.1007/s10434-000-0087-9
Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469-474.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.